D
89bio, Inc. ETNB
$8.18 -$0.17-2.04%
Recommendation
Sell
Prev Close
$8.35
Volume
420
Avg Vol (90D)
1,845,468
Market Cap
$1.22B
Dividend & Yield
--
52-Week Range
$5.99 - $13.71
P/E (TTM)
--
EPS (TTM)
-$3.43
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
D
Weak
Rating Factors
Growth Index
Very Weak
Efficiency Index
Very Weak
Solvency Index
Excellent
Total Return Index
Weak
Volatility Index
Weak
Dividend Index
--
Headlines
89bio (ETNB, $8.18) Stochastic Oscillator left the oversold zone on March 13, 2025
3/14/2025 - Tickeron - Stocks
89bio initiated with a Neutral at Goldman Sachs
3/14/2025 - TipRanks Financial Blog
89bio initiated with neutral view at Goldman Sachs, here's why
3/14/2025 - The Fly
89bio (ETNB) Receives a New Rating from Goldman Sachs
3/14/2025 - TipRanks Financial Blog
89bio (NASDAQ:ETNB) Stock Price Up 5.8% - What's Next?
3/13/2025 - MarketBeat
Commit To Buy 89bio At $7.50, Earn 25.1% Annualized Using Options
3/13/2025 - Stock Options Channel
89bio (ETNB, $8.35) RSI Indicator left the oversold zone on March 12, 2025
3/13/2025 - Tickeron - Stocks
89bio initiated with bullish view at Citi, here's why
3/13/2025 - The Fly
Bears are Losing Control Over 89BIO (ETNB), Here's Why It's a 'Buy' Now
3/12/2025 - Zacks Investment Research
89bio (ETNB, $7.85) RSI Indicator left the oversold zone on March 07, 2025
3/8/2025 - Tickeron - Stocks
89bio (NASDAQ:ETNB) Announces Quarterly Earnings Results, Misses Expectations By $0.42 EPS
3/8/2025 - Ticker Report
89bio (NASDAQ:ETNB) Earns Sell (D-) Rating from Weiss Ratings
3/8/2025 - MarketBeat
Cantor Fitzgerald Forecasts Stronger Earnings for 89bio
3/7/2025 - MarketBeat
Is 89BIO (ETNB) Stock Outpacing Its Medical Peers This Year?
3/6/2025 - Zacks Investment Research
89bio (ETNB, $8.48) price exceeded its 50-day Moving Average on March 04, 2025
3/5/2025 - Tickeron - Stocks
89bio (ETNB) Shares Cross Below 200 DMA
3/4/2025 - Market News Video
89bio Inc (ETNB) to Participate in Leerink Partners Global Healthcare Conference
3/3/2025 - GuruFocus
89bio to Participate in the Leerink Partners Global Healthcare Conference
3/3/2025 - GuruFocus
89bio to Participate in the Leerink Partners Global Healthcare Conference
3/3/2025 - Globe Newswire
Analysts Conflicted on These Healthcare Names: Cytokinetics (CYTK), Warby Parker (WRBY) and 89bio (ETNB)
3/3/2025 - TipRanks Financial Blog
Bank of America Securities Keeps Their Buy Rating on 89bio (ETNB)
3/2/2025 - TipRanks Financial Blog
HC Wainwright Reiterates "Buy" Rating for 89bio (NASDAQ:ETNB)
3/1/2025 - MarketBeat
89Bio Inc. Faces Financial Risks Amid Market Challenges for Approved Products
3/1/2025 - TipRanks Financial Blog
89bio Inc. Advances Clinical Trials Amid Financial Losses
3/1/2025 - TipRanks Financial Blog
89bio (NASDAQ:ETNB) Announces Earnings Results, Misses Estimates By $0.42 EPS
3/1/2025 - MarketBeat
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$384.62M
EBIT (TTM)
-$384.66M
Net Income (TTM)
-$367.08M
Balance Sheet
Total Assets (Q)
$478.69M
Total Debt (Q)
$37.55M
Total Liabilities (Q)
$77.90M
Book Value Per Share (Q)
$3.34
Cash Flow
Cash from Operations (TTM)
-$367.82M
Cash from Investing (TTM)
-$40.86M
Cash from Financing (TTM)
$218.59M
Net Change in Cash (TTM)
-$190.10M
Filings
Filing Date
Thursday, February 27, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 5 and 9 (est)
Price History
Loading...
Beta
1.70
7-Day Total Return
-3.54%
30-Day Total Return
-6.30%
60-Day Total Return
4.20%
90-Day Total Return
2.38%
Year to Date Total Return
2.51%
1-Year Total Return
-38.54%
2-Year Total Return
-35.18%
3-Year Total Return
137.10%
5-Year Total Return
-64.47%
52-week Low
Jan 16, 2025 - $5.99
52-week High
Mar 18, 2024 - $13.71
Valuation
Market Cap
$1.22B - Small Cap
Enterprise Value
$816.56M
Price/Sales (TTM)
--
Price/Book (Q)
2.50
Dividends and Shares
Shares Outstanding
115.96M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.89bio.com
Phone Number
415 432 9270
Address
142 Sansome Street
San Francisco, CA 94104
Country
United States
Year Founded
2018
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product... more
NASDAQ 03/13/2025 4:00PM Eastern Quotes delayed
Weiss Ratings